Two Sigma Advisers LP Has $247.54 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Two Sigma Advisers LP cut its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 45.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,330,500 shares of the biopharmaceutical company's stock after selling 7,622,100 shares during the period. Two Sigma Advisers LP owned approximately 0.16% of Pfizer worth $247,538,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Rialto Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at about $27,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $31,000. Finally, Curio Wealth LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

PFE stock traded up $0.51 during mid-day trading on Tuesday, reaching $23.51. 56,982,321 shares of the stock traded hands, compared to its average volume of 41,026,680. The firm has a market capitalization of $133.66 billion, a PE ratio of 16.67, a P/E/G ratio of 0.64 and a beta of 0.58. The business has a 50-day moving average of $23.56 and a two-hundred day moving average of $25.27. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the firm posted $0.82 EPS. The company's revenue was down 7.8% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.32%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is currently 124.64%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.